Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H17N5 |
| Molecular Weight | 255.3183 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CN1C(C)=NC2=C1C3=NC=CC=C3N=C2N
InChI
InChIKey=ZXBCLVSLRUWISJ-UHFFFAOYSA-N
InChI=1S/C14H17N5/c1-8(2)7-19-9(3)17-12-13(19)11-10(18-14(12)15)5-4-6-16-11/h4-6,8H,7H2,1-3H3,(H2,15,18)
| Molecular Formula | C14H17N5 |
| Molecular Weight | 255.3183 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sotirimod is designed to treat actinic keratosis and other conditions and is a follow-up of Aldara (active substance: imiquimod). Sotirimod and imiquimod are immunomodulatory drugs that activate the body's immune system to combat skin changes such as actinic keratosis. Sotirimod is immunostimulants and Toll-like receptor 7 agonist. Sotirimod was originally developed by 3M Pharmaceuticals, then licensed to Meda in Europe for the treatment of actinic keratosis in 2007. Sotirimod had been in phase III development for the treatment of actinic keratosis. However, there is no recent development report for this study.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:04:07 GMT 2023
by
admin
on
Fri Dec 15 16:04:07 GMT 2023
|
| Record UNII |
X04FQM7J4M
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C308
Created by
admin on Fri Dec 15 16:04:07 GMT 2023 , Edited by admin on Fri Dec 15 16:04:07 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6450818
Created by
admin on Fri Dec 15 16:04:07 GMT 2023 , Edited by admin on Fri Dec 15 16:04:07 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107373
Created by
admin on Fri Dec 15 16:04:07 GMT 2023 , Edited by admin on Fri Dec 15 16:04:07 GMT 2023
|
PRIMARY | |||
|
227318-75-4
Created by
admin on Fri Dec 15 16:04:07 GMT 2023 , Edited by admin on Fri Dec 15 16:04:07 GMT 2023
|
PRIMARY | |||
|
X04FQM7J4M
Created by
admin on Fri Dec 15 16:04:07 GMT 2023 , Edited by admin on Fri Dec 15 16:04:07 GMT 2023
|
PRIMARY | |||
|
DB05680
Created by
admin on Fri Dec 15 16:04:07 GMT 2023 , Edited by admin on Fri Dec 15 16:04:07 GMT 2023
|
PRIMARY | |||
|
300000034448
Created by
admin on Fri Dec 15 16:04:07 GMT 2023 , Edited by admin on Fri Dec 15 16:04:07 GMT 2023
|
PRIMARY | |||
|
C76687
Created by
admin on Fri Dec 15 16:04:07 GMT 2023 , Edited by admin on Fri Dec 15 16:04:07 GMT 2023
|
PRIMARY | |||
|
RR-12
Created by
admin on Fri Dec 15 16:04:07 GMT 2023 , Edited by admin on Fri Dec 15 16:04:07 GMT 2023
|
PRIMARY | |||
|
8718
Created by
admin on Fri Dec 15 16:04:07 GMT 2023 , Edited by admin on Fri Dec 15 16:04:07 GMT 2023
|
PRIMARY | |||
|
DTXSID80177269
Created by
admin on Fri Dec 15 16:04:07 GMT 2023 , Edited by admin on Fri Dec 15 16:04:07 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
